New Abbott drug atrasentan reduces proteinuria in diabetic kidney disease. PDF Print
Bloomberg: Abbott Laboratories said Monday its drug candidate atrasentan met key goals in a midstage study aimed at treating chronic kidney disease.

...

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.